Obinepitide

Mechanism of action

Obinepitide is built to act like two of the body's own meal signals at once. After eating, the gut releases peptide YY, which dampens appetite mainly through the Y2 receptor, and pancreatic polypeptide, which does the same mainly through the Y4 receptor; obinepitide is a single peptide analogue that engages both receptors, which 7TM Pharma described as a first-in-class, dual Y2-Y4 agonist reaching the two receptors with similar, high potency (7TM Pharma announcement, 2006; DrugBank DB05045). Its listed structure is that of a pancreatic-polypeptide analogue (NCATS Inxight / FDA GSRS UNII 926PP306RV; formula C185H288N54O55S2). The company's stated rationale was that adding Y4 activity to the Y2 activity of peptide YY would curb appetite more fully than peptide YY alone; it reported that in diet-induced obese animals obinepitide reduced body weight over the long term more than PYY3-36, which acts only at Y2. The 2024 review carded below places it among the newer pancreatic-polypeptide-derived ligands built on this receptor system (PMID 38430725). How the mechanism behaves over months in people was never reported.

Primary uses

• Investigational: obesity (phase I/II and phase II completed in the 2000s, company-reported, no published results; development dormant)

Typical dosing

Regulatory status

Not approved anywhere: Drugs@FDA and the openFDA label endpoint hold no record for obinepitide or TM30338 (searched November 5, 2026), and ChEMBL records a highest clinical phase of 2 (CHEMBL2108338). 7TM Pharma said it completed a phase I/II study in adults with obesity in 2006 and began a phase II study in 2007, but no trial of obinepitide is registered on ClinicalTrials.gov and no result was published in a peer-reviewed journal. The company's only registered trial, NCT00746824, tested a different molecule, its Y4-selective agonist TM30339, and was terminated in 2009. Development of obinepitide appears to have stopped.

Status as of this entry's last review, November 5, 2026. Approvals, compounding rules and sport rules change; the regulatory tracker is checked more often.

What the studies show

PubMed holds one record that names obinepitide, a 2024 review of the Y4 receptor and pancreatic polypeptide, carded below; it describes the drug's target and stage, not trial results. Everything known about obinepitide in people comes from 7TM Pharma's own announcements in the 2000s, none of them a peer-reviewed paper and none carried on ClinicalTrials.gov. The company said that in a phase I/II study in adults with obesity a once-daily injection under the skin lowered food intake for at least nine hours after dosing and was safe and well tolerated, that the study met its goals, and that it began a phase II study in obesity in 2007. It also reported that in obese animals the drug reduced weight over the long term more than PYY3-36. No numbers for weight change in people, and no trial report, were ever published, and development appears to have stopped.

References

1. [pubmed] Schüß C, et al. "Illuminating the neuropeptide Y(4) receptor and its ligand pancreatic polypeptide from a structural, functional, and therapeutic perspective." Neuropeptides, 2024;105:102416. PMID: 38430725.
2. [other] ChEMBL molecule CHEMBL2108338 (OBINEPITIDE), read November 5, 2026: molecule type Protein; synonyms Obinepitide, Obinepitida, TM-30338 and TM30338; highest clinical phase recorded 2. https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108338/
3. [other] FDA Global Substance Registration System / NCATS Inxight Drugs, Obinepitide, UNII 926PP306RV (CAS 348119-84-6; code names TM-30338 and TM30338), read November 5, 2026: a synthetic analogue of the pancreatic-polypeptide family, catalogued under the systematic name "(34-L-glutamine)pancreatic hormone (human)". https://drugs.ncats.io/drug/926PP306RV
4. [other] DrugBank DB05045 (Obinepitide), read November 5, 2026: a synthetic analogue of the two meal-released human hormones PYY and pancreatic polypeptide, listed as a first-in-class compound that in one drug targets both the Y2 and the Y4 receptor; molecular formula C185H288N54O55S2, average mass 4212.78 Da; targets neuropeptide Y receptor type 2 (NPY2R, P49146) and type 4 (NPY4R, P50391); investigated in obesity. https://go.drugbank.com/drugs/DB05045
5. [manufacturer] 7TM Pharma A/S announcement, reported March 22, 2006 (bionity.com, "7TM Pharma's new first-in-class anti-obesity drug completes Phase I/II clinical studies"): the company said TM30338 (obinepitide), a dual Y2-Y4 receptor agonist and synthetic analogue of PYY and pancreatic polypeptide, met both the primary and secondary objectives of a phase I/II study in obese adults, where once-daily subcutaneous dosing inhibited food intake at a statistically significant level up to at least 9 hours after dosing and the drug was safe and well tolerated; a larger phase IIa study was being planned. Company statements. https://www.bionity.com/en/news/53309. Read November 5, 2026.
6. [manufacturer] 7TM Pharma A/S press release, reported June 12, 2007 (BioSpace, "7TM Pharma Initiates Phase II Clinical Study with the Drug Candidate Obinepitide for the Treatment of Obesity"): the company said it had started a phase II study of obinepitide (TM30338), described as a close analogue of two natural hormones with different mechanisms of action, for obesity and related diseases. Company statements. https://www.biospace.com/7tm-pharma-initiates-phase-ii-clinical-study-with-the-drug-candidate-obinepitide-for-the-treatment-of-obesity. Read November 5, 2026.
7. [other] US FDA, Drugs@FDA and the drug label endpoint (openFDA), searched November 5, 2026: no application and no label record for obinepitide or TM30338.

Related peptides

Guides & tools